BioLight Announces Joint Investment in IOPtima Subsidiary

BioLight announced today that it has entered into a joint financing agreement with two Asia-based venture capital firms, pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight’s  IOPtima Ltd. subsidiary via a private placement. The financing will help IOPtima to continue the global commercialization of its innovative IOPtimateTM system used in the treatment of glaucoma, as well as to initiate a regulatory approval pathway process for the IOPtimateTM system with the U.S. Food and Drug Administration, commencing 2016.

Link to complete article

Link to Newsroom

Comments are closed.